About us
Artificial Intelligence and Bioinformatics for Precision Medicine
Our story
Ardigen is recognized among the top 5% of AI-driven Contract Research Organizations (CRO), dedicated to transforming drug discovery with the highest precision.
For over nine years, we’ve earned the trust of more than 100 clients, including 15 of the world’s leading pharmaceutical companies, by delivering solutions tailored to their unique challenges. Our expertise in biology, bioinformatics, machine learning, and software engineering helps our clients accelerate drug discovery, increase the probability of clinical success, and solve the industry’s most complex problems.
Our mision:
Deliver medicines to patients faster by transforming biomedical data into actionable insights.
Our vision:
Accelerate drug development and increase the probability of success in creating effective treatments.
Our “Why”
At Ardigen, we’re committed to advancing human health by helping our clients bring effective treatments to patients faster. Every solution we deliver is driven by a core belief: People First. Whether we’re developing AI algorithms or offering our deep expertise, focus is always on enhancing human life and well-being.
Our clients gain access to advanced tools and industry-leading expertise, designed to significantly increase the probability of success in developing effective treatments. We partner closely with biotech and pharma companies, empowering them with the technology and insights they need to solve their most critical challenges in drug development.
Our values guide our actions, not just adorn the wall
Trust
We build relationships based on integrity and transparency.
Knowledge
We continuously expand our expertise to stay at the forefront of our field.
Persistence
We are dedicated to overcoming challenges and achieving our goals.
Quality
We strive for excellence in everything we do.
Leadership
Our leadership team consists of visionaries who bring extensive experience and a deep understanding of the life sciences and technology sectors. They are committed to driving innovation and fostering a culture that prioritizes human life and scientific advancement. Their strategic vision and dedication to excellence propel Ardigen to the forefront of AI-driven drug discovery.
Management Board
Mr. Janusz Homa is the co-founder and Chief Executive Office of Ardigen S.A. responsible for strategic management, business and corporate development.
He began his career in 1994 in Comarch where, among others he was the Vice-President of the Management Board of the subsidiary Comarch Telecom. In 2000 he founded one of the first venture capital funds in Poland investing in ventures based on new technologies. Between 2002 and 2005 he implemented Polish alternative payment network.
From 2006 to 2013 he was the President of the Management Board of Software Mind (currently Ailleron listed on Warsaw Stock Exchange) of which he was the founder and major shareholder. During this period, the company employed 300 people, gained a strong position in the financial and telecommunications industry and launched their own, ground-breaking products LiveBank and iLumio on the international markets.
Livia Legg has a distinguished career in global business development, sales and marketing leadership, most recently serving as Chief Commercial Officer at Shanghai ChemPartner and General Manager of ChemPartner Corporation US & EU from 2015. Livia’s career also spans international leadership positions including Vice President, Executive Director, and Head of Global Business Development at QPS, LLC from 2002 to 2015 and earlier strategic roles at MDS Pharma Services and Merck Pharmaceutical Company since 1997.
Livia holds a Bachelor of Science (BS) degree in Nutritional Sciences and a Master of Science (M.S.) degree in Molecular, Cellular & Biomedical Science from the University of New Hampshire.
Lukasz Nowak joined Ardigen in 2018 and currently holds the position of the Chief Operating Officer. He has over 14 years of experience in the IT industry in software development and management roles. He has participated in and managed multiple software projects andcreated IT products for new markets. From 2004 to 2015 he played a number of roles in Software Mind (currently Ailleron listed on Warsaw Stock Exchange), starting as a software engineer and advancing to general manager of iLumio Business Unit. From 2016 to 2017 he was running and building technology practice at VML Poland as Chief Technology Officer, managing a team of more than 100 professionals. He holds a master degree in computer science from AGH University of Science and Technology.
Dr. Michał Warchoł focuses on the development and applications of computer vision algorithms for accelerating the drug discovery process. Michał joined Ardigen in 2016 to build Data Science and Machine learning capabilities and expertise within Ardigen AI Labs. Currently, Michal is a General Director of the Biomedical Imaging Business Unit that strives to improve both clinical and preclinical stages of the drug discovery process by leveraging information contained in images. Michal did a PhD in Statistics at the Institute of Statistics, Biostatistics and Actuarial Sciences at Université Catholique de Louvain in Belgium. Part of his research program was conducted at the Department of Statistics at Columbia University in New York. Prior to joining Ardigen, Dr. Warchoł co-founded DeepArt UG, a company providing novel image processing algorithms based on deep learning.
Supervisiory
Board
Mr. Przewiezlikowski is the Chief Executive Officer and founder of Ryvu Therapeutics, responsible for strategic management, business and corporate development of the company. He is also the President of the Supervisory Board at Ardigen and Member of the Supervisory Board at Selvita. Before founding multiple companies in the biotechnology sector (Ryvu, Ardigen, NodThera), he was a member of the executive team at technology company Comarch, responsible for divisions involved in multiple industries, including the pharmaceutical industry. He was also the co-founder, the first CEO and then the Vice President of the Supervisory Board of Interia.pl, the third largest Internet portal in Poland.
Mr. Przewiezlikowski is a member of the Economic Council of the Malopolska (Krakow) region. He was awarded Knight’s Cross of the Order of Polonia Restituta for his contributions to the development of Poland’s business environment, as well as, EY Entrepreneur of the Year 2015 award in the New Technologies/Innovation category in Poland. He holds an MBA from the joint program of the Teesside University (United Kingdom) and Krakow School of Economics (Poland) as well as a master degree in computer science from AGH Technical University in Krakow. He also studied IT at the Technical University in Berlin.
Dr. Brzozka is the Chief Scientific Officer at Ryvu Therapeutics and a board member of Ardigen. He joined Ryvu Therapeutics in 2007 and has applied his interdisciplinary expertise ever since, in order to build a broad pipeline of small molecule oncology therapeutics and a high throughput discovery engine platform. Dr. Brzozka is responsible for the management of the early pipeline candidates, covering their full development until clinical phase. He is also responsible for bringing into the clinic two Ryvu first-in-class oncology programs: dual PIM/FLT3 inhibitor SEL24/MEN1703 and SEL120, CDK8 inhibitor. Dr. Brzozka has also contributed to the founding of NodThera, a biotechnology company focused on therapeutics related to inflammasome biology.
Dr. Brzozka holds a Ph.D. degree from Ludwig Maximilian University. He also earned an MBA from the Stockholm University School of Business and the Krakow University of Economics Business School. Dr. Brzozka contributed to over 20 peer reviewed publications in areas including intracellular signaling, immunology, and medicinal chemistry.
Mr. Boguslaw Sieczkowski is a co-founder of Selvita and currently holds the position of the Executive Vice President, as well as the Chief Operating Officer.
Mr. Sieczkowski has over 10 years of experience in management. His career was initiated in the mid-90s supervising computerization of companies within Bahlsen group. Since 2000 as a board member of Comarch Internet Ventures S.A. he developed the first ASP Services platform in Poland. Till 2007, as a Vice President of Comarch S.A. he was in charge of the largest subsector (250 people) delivering products for leading scientific and finance institutions.
Mr. Sieczkowski was awarded Knight’s Cross of the Order of Polonia Restituta for his contributions to the development of Poland’s business environment.
He holds an MBA from the joint programme of the University of Teesside (United Kingdom) and Krakow School of Economics (Poland), master degree in computer science from Jagiellonian University in Krakow as well as Project Management Professional certificate issued by Project Management Institute (United States).
Mr. Tomasz Piętka is a founder of Silvergrass Capital Partners, a private equity/venture capital company. His over 25 years professional experience in capital markets and growth management includes: full cycle private equity/venture capital fund management in Central and Eastern Europe (Enterprise Investors/Vice President and bmp Poland/ Managing Director), strategic M&A transactions (Computerland/ Sygnity M&A Director) and capital transactions advisory. He personally participated in over 100 M&A transactions, in total was a member of 30 supervisory boards. His experience covers almost all sectors with focus on small and medium sized businesses.
Mr. Tomasz Piętka graduated from University of Gdańsk (Economy/Foreign Trade). He continued education at The University of Michigan and The Wharton School (University of Pennsylvania).
Prior to starting his business activities, Mr. Tomasz Piętka was a professional football player.
Advisiory
Board
Mariola Fotin-Mleczek, PhD, has over 20 years of experience in developing and optimizing the broad spectrum of therapeuticals mainly based on messenger RNA (mRNA) for medical purposes. She has co-authored over 30 scientific publications with the main focus on the multiple patented mRNA-based therapies (mainly vaccines).
Mariola Fotin-Mleczek, PhD, is an internationally recognized specialist in the field of immunology and cell biology. For nearly 16 years, she worked for CureVac, the global biopharmaceutical company and took responsibility as Chief Scientific and Chief Technology Officer. Her revolutionary work has supported multiple clinical trials with cancer therapies, prophylactic vaccines, and development of antibody therapies. She is the inventor of RNActive® related key patents. In 2021, Mariola Fotin-Mleczek, PhD, was named one of the Top 25 Women Leaders in Biotechnology. For Ardigen, it is the opportune time to work even more effectively on new therapeutics in clinical development to support and guide healthcare needs in the development of medicine.
Guy Cavet is a biotech executive and computational biologist, focused on improving human health through advances in technology. He has over twenty years of experience in applying computation to therapeutics and diagnostics R&D. Guy has co-founded Atreca and Paramune, and has led informatics and computational biology teams at companies including Genentech, Merck, Rosetta Inpharmatics and Crescendo Bioscience. His extensive experience also includes establishing and leading technology-driven partnerships to enable clinical research and drug development.
“I have enjoyed collaborating with Ardigen as a partner for several years, and I am delighted to join the company’s Advisory Board” said Dr. Cavet. “The importance of computational tools in drug discovery and development is only increasing, from robust data management to advanced machine learning. I look forward to helping Ardigen advance their technology suite and deliver value in pharmaceutical R&D”.
Contact
Ready to transform drug discovery?
Leave us a message and we will reach out to you within 24 hours, to tell you more about how we can empower your drug development journey.
Send us a message and we will contact you back within 48 hours.
Newsletter
Become an insider
Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!
